Based in Hwasun-gun, South Korea, CNCure develops innovative solutions for the early diagnosis and effective treatment of diseases, particularly cancer. Their offerings include a microbial platform for cancer therapy, molecular imaging spies for informed decision-making, and a radio-theranostics platform for simultaneous disease diagnosis and treatment. They focus on developing radiopharmaceuticals and bacterial-based cancer therapies, with drug candidates like 18F-DMPY2 for skin cancers and 18F-FDS for fungal infections. CNCure's expertise lies in combining radioactive drugs to identify and deliver therapy to tumors, targeting both the main tumor and any metastatic tumors.